Cost-Effectiveness Analysis of Sacubitril/Valsartan for Reducing the Use of Implantable Cardioverter-Defibrillator (ICD) and the Risk of Death in ICD-Eligible Heart Failure Patients with Reduced Ejection Fraction
المؤلف | Kaddoura, Rasha |
المؤلف | Abushanab, Dina |
المؤلف | Arabi, Abdul Rahman |
المؤلف | Alyafei, Sumaya Alsaadi |
المؤلف | Al-Badriyeh, Daoud |
تاريخ الإتاحة | 2023-05-11T04:02:27Z |
تاريخ النشر | 2022-12-01 |
اسم المنشور | Current Problems in Cardiology |
المعرّف | http://dx.doi.org/10.1016/j.cpcardiol.2022.101385 |
الرقم المعياري الدولي للكتاب | 01462806 |
الملخص | Although previous cost‐effectiveness evaluations of sacubitril/valsartan have demonstrated cardiovascular and economic benefits in heart failure patients with reduced ejection fraction (HFrEF), whether sacubitril/valsartan is cost-effective for reducing the need for implantable cardioverter-defibrillator (ICD) implantation and the risk of death in ICD‐eligible patients has not been investigated in patients with HFrEF. Herein, we evaluated the cost-effectiveness of sacubitril/valsartan versus standard of care in reducing the need for ICD implantation and the death rate in HFrEF. A Markov model was developed from the Qatari hospital perspective, comprised of ‘survival’ and ‘death’ health states, and was based on 1-monthly Markovian cycles, a 20-years follow-up horizon, and a 3% discount rate. The model inputs were obtained from the literature and local sources. Sacubitril/valsartan resulted in a relative increase of 0.04 quality-adjusted life year (QALY) and 0.67 years of life lived (YLL)/person, with an incremental cost increase of QAR13,952 (USD3,832). Sacubitril/valsartan was associated with incremental cost effectiveness ratio of QAR341,113 (USD93,687)/QALYs gained and QAR24,431 (USD6,710)/YLL. Sensitivity analyses confirmed robustness, with the cost-effectiveness maintained in ≥96.5% of simulated cases. To conclude, sacubitril/valsartan is a cost-effective alternative to standard care against QALY gained and YLL in reducing the need for an ICD therapy and the rate of death among ICD-eligible HFrEF patients. |
اللغة | en |
الناشر | Elsevier |
الموضوع | Sacubitril/Valsartan Implantable Cardioverter-Defibrillator (ICD) |
النوع | Article |
رقم العدد | 12 |
رقم المجلد | 47 |
تحقق من خيارات الوصول
الملفات في هذه التسجيلة
هذه التسجيلة تظهر في المجموعات التالية
-
أبحاث الصيدلة [1261 items ]